NewAmsterdam Pharma Company N.V.

NAMS Healthcare Biotechnology

NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024. In the quarter to June 2026, revenue fell 80.7%, EPS fell 246.7% and free cash flow fell 4.07%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

19.83 0.79 −3.83%
Market cap
$2.5B
P/E
0.0×
Fwd P/E
−17.5×
Dividend yield
—
F-score
3/9
Altman Z
27.63
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

— 3 3 2
ROE
(39.94%) (28.29%) (29.49%) (36.81%)
ROA
(36.08%) (24.95%) (27.43%) (34.16%)
ROIC
(532.55%) (307.51%) (484.09%) 0.00%
Return on Tangible Assets
(32.78%) (34.53%) (36.00%) (44.24%)
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(1.21) (1.25) (1.17) (1.16)
Free Cash Flow
(144.54) (148.03) (142.19) (143.72)
Capital Expenditures
(0.15) (0.25) (0.27) (0.26)
Other line items
Cash ROIC
(10.09%) (11.21%) (10.92%) (11.35%)
Accounts Receivable Turnover
0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
391.94% 630.28% 598.67% 2,095.87%
Selling, General and Administrative Expense of Revenue
283.86% 472.62% 454.92% 1,436.33%
Share Based Compensation of Revenue
155.54% 264.08% 275.71% 918.64%
Operating CF/Net income
0.65 0.73 0.67 0.55
Depreciation/Fixed assets
0.66 0.57 0.61 0.59
Capex/Depreciation
(0.70) (1.12) (1.17) (1.07)
Revenue per Share
0.30 0.19 0.19 0.06
Operating CF per Share
(1.21) (1.25) (1.17) (1.16)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.01 0.01 0.04

Fold the line items

Columns are period end dates